Nilofabicin (CG-400549) is an experimental antibiotic medication related to afabicin, which acts as an inhibitor of the bacterial enzyme enoyl-acyl carrier protein reductase (FabI). It is being researched as a potential treatment for infections by drug-resistant strains of bacteria such as "Staphylococcus aureus", "Klebsiella pneumoniae" and "Pseudomonas aeruginosa".